Tags

Type your tag names separated by a space and hit enter

Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat.
Eur J Pharmacol. 2001 Apr 20; 418(1-2):105-10.EJ

Abstract

Ranolazine reduces cellular acetyl-CoA content via inhibition of fatty acid beta-oxidation and activates pyruvate dehydrogenase. This metabolic switch increases ATP production per mole of oxygen consumed, reduces the rise in lactic acid and acidosis, and maintains myocardial function under conditions of reduced myocardial oxygen delivery. It is still unclear whether ranolazine causes a reduction of (i) infarct size and (ii) cardiac troponin T release, in a male Wistar rat model of left anterior descending coronary artery occlusion (25 min) and reperfusion (2 h). Rats were subjected to saline infusion (n=12) or ranolazine (bolus injection: 10 mg/kg plus infusion: 9.6 mg/kg/h, n=12), 30 min prior to left anterior descending coronary artery occlusion-reperfusion, respectively. Ranolazine caused a significant reduction in myocardial infarct size of approximately 33% compared to saline control (P<0.05). In addition, infusion of ranolazine significantly attenuated the release of cardiac troponin T into the plasma from 65+/-14 (controls) to 12+/-2 ng/ml. This study demonstrates for the first time that ranolazine significantly reduces (i) infarct size and (ii) cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion.

Authors+Show Affiliations

Department of Cardiac, Vascular and Inflammation Research, The William Harvey Research Institute, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, EC1M 6BQ, London, UK. k.zacharowski@mds.qmw.ac.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11334871

Citation

Zacharowski, K, et al. "Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, Reduces Myocardial Infarct Size and Cardiac Troponin T Release in the Rat." European Journal of Pharmacology, vol. 418, no. 1-2, 2001, pp. 105-10.
Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001;418(1-2):105-10.
Zacharowski, K., Blackburn, B., & Thiemermann, C. (2001). Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. European Journal of Pharmacology, 418(1-2), 105-10.
Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a Partial Fatty Acid Oxidation Inhibitor, Reduces Myocardial Infarct Size and Cardiac Troponin T Release in the Rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10. PubMed PMID: 11334871.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. AU - Zacharowski,K, AU - Blackburn,B, AU - Thiemermann,C, PY - 2001/5/4/pubmed PY - 2001/9/28/medline PY - 2001/5/4/entrez SP - 105 EP - 10 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 418 IS - 1-2 N2 - Ranolazine reduces cellular acetyl-CoA content via inhibition of fatty acid beta-oxidation and activates pyruvate dehydrogenase. This metabolic switch increases ATP production per mole of oxygen consumed, reduces the rise in lactic acid and acidosis, and maintains myocardial function under conditions of reduced myocardial oxygen delivery. It is still unclear whether ranolazine causes a reduction of (i) infarct size and (ii) cardiac troponin T release, in a male Wistar rat model of left anterior descending coronary artery occlusion (25 min) and reperfusion (2 h). Rats were subjected to saline infusion (n=12) or ranolazine (bolus injection: 10 mg/kg plus infusion: 9.6 mg/kg/h, n=12), 30 min prior to left anterior descending coronary artery occlusion-reperfusion, respectively. Ranolazine caused a significant reduction in myocardial infarct size of approximately 33% compared to saline control (P<0.05). In addition, infusion of ranolazine significantly attenuated the release of cardiac troponin T into the plasma from 65+/-14 (controls) to 12+/-2 ng/ml. This study demonstrates for the first time that ranolazine significantly reduces (i) infarct size and (ii) cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion. SN - 0014-2999 UR - https://www.unboundmedicine.com/medline/citation/11334871/Ranolazine_a_partial_fatty_acid_oxidation_inhibitor_reduces_myocardial_infarct_size_and_cardiac_troponin_T_release_in_the_rat_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(01)00920-7 DB - PRIME DP - Unbound Medicine ER -